Thank you to everyone who participated in the recent ATCC Innovation Challenge! Through this challenge, we called upon innovators throughout the scientific community to submit a proposal of how they are using ATCC products in a novel way in infectious respiratory disease research or COVID-19 research. After receiving numerous submissions, we are pleased to announce the four winners of the challenge below. We’re proud to be a part of the scientific community that is working toward solving the COVID-19 crisis and we look forward to these innovative ideas coming to fruition.

Congratulations to our winners

Kartik Balachandran, University of Arkansas
This study focuses on the development of a novel nasal-airway-lung organ-on-chip device that mimics upper and lower respiratory tract physiology during viral exposure, enabling critical research on disease pathology and the identification of therapeutic targets for SARS-CoV-2 and other respiratory diseases.

Gopal Iyer, University of Wisconsin Madison
This research seeks to establish the mechanistic framework of the inflammatory response in COVID-19 patients through gender-specific interrogation and to explore the use of hormone antagonists as a potential mechanism of action for dampening the exacerbated inflammatory signal.

Pengda Liu, University of North Carolina at Chapel Hill
This study takes an innovative approach toward COVID-19 treatment and prevention by evaluating the use of casein kinase I (CKI) antagonists in reducing the infection by of coronavirus.

Bocheng Wu, Georgia Institute Of Technology
Attenuation of the immune response and tissue inflammation is the key for treating COVID-19 patients. This research will evaluate the ability of several novel compounds to effectively and safely reduce inflammation during SARS-CoV-2 infection.

Products of interest:

 

Airway Epithelial Cell Basal Medium (ATCC PCS-300-030)

Bronchial Epithelial Cell Growth Kit  (ATCC PCS-300-040)

Fibroblast Basal Medium (ATCC PCS-201-030)

Fibroblast Growth Kit-Low serum  (ATCC PCS-201-041)

NuLi-1 (ATCC CRL-4011)

Primary Bronchial/Tracheal Epithelial Cells (ATCC PCS-300-010)

Primary Bronchial/Tracheal Epithelial Cells; Fibrosis  (ATCC PCS-300-014)

Primary Lung Fibroblast, Normal, Human (HLF) (ATCC PCS-201-013)

Primary Lung Fibroblast; Fibrosis (ATCC PCS-201-020)

Primary Lung Fibroblasts; Asthma (ATCC PCS-201-015)

Primary Bronchial/Tracheal Epithelial Cells; Asthma (ATCC PCS-300-011)

Quantitative Synthetic SARS-CoV [2003] RNA (ATCC VR-3280SD)

Virome Virus Mix  (ATCC MSA-2008)